[Off-label use of biological therapies in systemic diseases].
Hachulla
E
E
Service de médecine interne, centre de référence des maladies auto-immunes et maladies systémiques rares, sclérodermie systémique, hôpital Claude-Huriez, université de Lille-2, avenue Oscar-Lambret, 59037 Lille cedex, France. ehachulla@chru-lille.fr
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001691:Biological Therapy / Q000379:methods*; D003879:Dermatologic Agents / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D056687:Off-Label Use; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000093242:Interleukin-6 Inhibitors
D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D007155:Immunologic Factors; D007375:Interleukin-1; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors
Les biothérapies hors AMM dans les maladies systémiques.